Our data demonstrates that the oncogenic activity of WAVE3 can be driven by phosphorylation of its PRD domain, and targeting this PTM may serve as a potential therapeutic option for treating patients with TNBCs, thus preventing cancer progression and metastasis. Here, WASF3 is linked to cancer.